Parameter | 120 μg | 240 μg | Placebo |
---|---|---|---|
Number of patients evaluated | 36 | 41 | 35 |
Number of patients who experienced adverse events | 27 (75.0Â %) | 36 (87.8Â %) | 28 (80.0Â %) |
Number of patients who experienced serious adverse events | 3 (8.3Â %) | 4 (9.8Â %) | 1 (2.9Â %) |
Number of patients who discontinued the study treatment due to adverse events | 4 (11.1Â %) | 7 (17.1Â %) | 0 (0.0Â %) |
Number of patients who interrupted the study treatment due to adverse events | 0 (0.0Â %) | 2 (4.9Â %) | 0 (0.0Â %) |